AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Implementation Science In Cancer: Where Are We Today?
By The Cancer News Team
This article explores implementation science in cancer care, with insights from Fred Hutch’s Dr. Mazyar Shadman and the efforts of Binaytara and Dr. Binay Shah to reduce cancer disparities in LMICs.
Implementation Science In Cancer: Where Are We Today?
By The Cancer News Team
This article explores implementation science in cancer care, with insights from Fred Hutch’s Dr. Mazyar Shadman and the efforts of Binaytara and Dr. Binay Shah to reduce cancer disparities in LMICs.
Implementation Science In Cancer: Where Are We Today?
By The Cancer News Team
This article explores implementation science in cancer care, with insights from Fred Hutch’s Dr. Mazyar Shadman and the efforts of Binaytara and Dr. Binay Shah to reduce cancer disparities in LMICs.
Cancer Stigmas: The Invisible Barrier to Cancer Treatment in LMICs
By Binaytara Team
Cancer stigma in low- and middle-income countries (LMICs) hinders timely cancer screenings and treatments, especially for breast and cervical cancer, contributing to rising mortality.
Cancer Stigmas: The Invisible Barrier to Cancer Treatment in LMICs
By Binaytara Team
Cancer stigma in low- and middle-income countries (LMICs) hinders timely cancer screenings and treatments, especially for breast and cervical cancer, contributing to rising mortality.
Cancer Stigmas: The Invisible Barrier to Cancer Treatment in LMICs
By Binaytara Team
Cancer stigma in low- and middle-income countries (LMICs) hinders timely cancer screenings and treatments, especially for breast and cervical cancer, contributing to rising mortality.
FDA Approves Durvalumab For Muscle-Invasive Bladder Cancer
By The Cancer News Team
FDA approves durvalumab with chemotherapy as neoadjuvant and adjuvant treatment for muscle-invasive bladder cancer, showing improved survival in the NIAGARA trial.
FDA Approves Durvalumab For Muscle-Invasive Bladder Cancer
By The Cancer News Team
FDA approves durvalumab with chemotherapy as neoadjuvant and adjuvant treatment for muscle-invasive bladder cancer, showing improved survival in the NIAGARA trial.
FDA Approves Durvalumab For Muscle-Invasive Bladder Cancer
By The Cancer News Team
FDA approves durvalumab with chemotherapy as neoadjuvant and adjuvant treatment for muscle-invasive bladder cancer, showing improved survival in the NIAGARA trial.
From Glamor to Reality: How Tobacco Fuels the Lung Cancer Epidemic
By The Cancer News Team
This article explores how tobacco use drives the lung cancer epidemic and highlights efforts by Binaytara through CME conferences and the OncoBlast app to address cancer care disparities.
From Glamor to Reality: How Tobacco Fuels the Lung Cancer Epidemic
By The Cancer News Team
This article explores how tobacco use drives the lung cancer epidemic and highlights efforts by Binaytara through CME conferences and the OncoBlast app to address cancer care disparities.
From Glamor to Reality: How Tobacco Fuels the Lung Cancer Epidemic
By The Cancer News Team
This article explores how tobacco use drives the lung cancer epidemic and highlights efforts by Binaytara through CME conferences and the OncoBlast app to address cancer care disparities.
FDA Approves Cabozantinib for Adults and Pediatric Patients 12 Years of Age and Older With Pancreatic Neuroendocrine Tumors and Extra-Pancreatic Neuroendocrine Tumors
By The Cancer News Team
Cabozantinib receives FDA approval for treating advanced pancreatic and extra-pancreatic neuroendocrine tumors in patients 12 years and older, following positive CABINET trial results.
FDA Approves Cabozantinib for Adults and Pediatric Patients 12 Years of Age and Older With Pancreatic Neuroendocrine Tumors and Extra-Pancreatic Neuroendocrine Tumors
By The Cancer News Team
Cabozantinib receives FDA approval for treating advanced pancreatic and extra-pancreatic neuroendocrine tumors in patients 12 years and older, following positive CABINET trial results.
FDA Approves Cabozantinib for Adults and Pediatric Patients 12 Years of Age and Older With Pancreatic Neuroendocrine Tumors and Extra-Pancreatic Neuroendocrine Tumors
By The Cancer News Team
Cabozantinib receives FDA approval for treating advanced pancreatic and extra-pancreatic neuroendocrine tumors in patients 12 years and older, following positive CABINET trial results.
March is Multiple Myeloma Awareness Month What You Need to Know
By The Cancer News Team
March is Multiple Myeloma Awareness Month, a time to educate, inspire, and support patients and caregivers. Learn about myeloma symptoms, treatment advancements, disparities, and the latest expert insights on managing this blood cancer.
March is Multiple Myeloma Awareness Month What You Need to Know
By The Cancer News Team
March is Multiple Myeloma Awareness Month, a time to educate, inspire, and support patients and caregivers. Learn about myeloma symptoms, treatment advancements, disparities, and the latest expert insights on managing this blood cancer.
March is Multiple Myeloma Awareness Month What You Need to Know
By The Cancer News Team
March is Multiple Myeloma Awareness Month, a time to educate, inspire, and support patients and caregivers. Learn about myeloma symptoms, treatment advancements, disparities, and the latest expert insights on managing this blood cancer.
The FDA approves a new drug for HER2-positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1
By The Cancer News Team
The FDA has approved pembrolizumab in combination with trastuzumab and chemotherapy as a first-line treatment for HER2-positive gastric or GEJ adenocarcinoma expressing PD-L1 (CPS ≥ 1), based on improved survival outcomes in a Phase 3 clinical trial.
The FDA approves a new drug for HER2-positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1
By The Cancer News Team
The FDA has approved pembrolizumab in combination with trastuzumab and chemotherapy as a first-line treatment for HER2-positive gastric or GEJ adenocarcinoma expressing PD-L1 (CPS ≥ 1), based on improved survival outcomes in a Phase 3 clinical trial.
The FDA approves a new drug for HER2-positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1
By The Cancer News Team
The FDA has approved pembrolizumab in combination with trastuzumab and chemotherapy as a first-line treatment for HER2-positive gastric or GEJ adenocarcinoma expressing PD-L1 (CPS ≥ 1), based on improved survival outcomes in a Phase 3 clinical trial.
A New Combination in Kidney Cancer Therapy: High Doses of Seleno-L-Methionine and Axitinib in a Phase I Trial
By Dr. Yousef Zakharia
A Phase I trial explores the safety, efficacy, and tumor-suppressing effects of high-dose Seleno-L-Methionine (SLM) with Axitinib in metastatic clear cell renal carcinoma (mccRCC), showing promising early results.
A New Combination in Kidney Cancer Therapy: High Doses of Seleno-L-Methionine and Axitinib in a Phase I Trial
By Dr. Yousef Zakharia
A Phase I trial explores the safety, efficacy, and tumor-suppressing effects of high-dose Seleno-L-Methionine (SLM) with Axitinib in metastatic clear cell renal carcinoma (mccRCC), showing promising early results.
A New Combination in Kidney Cancer Therapy: High Doses of Seleno-L-Methionine and Axitinib in a Phase I Trial
By Dr. Yousef Zakharia
A Phase I trial explores the safety, efficacy, and tumor-suppressing effects of high-dose Seleno-L-Methionine (SLM) with Axitinib in metastatic clear cell renal carcinoma (mccRCC), showing promising early results.
Is Artificial Intelligence Echoing Human Bias in Cancer Care?
By The Cancer News Team
Exploring AI’s role in cancer care, from early diagnosis to drug discovery, while addressing bias and health disparities.
Is Artificial Intelligence Echoing Human Bias in Cancer Care?
By The Cancer News Team
Exploring AI’s role in cancer care, from early diagnosis to drug discovery, while addressing bias and health disparities.
Is Artificial Intelligence Echoing Human Bias in Cancer Care?
By The Cancer News Team
Exploring AI’s role in cancer care, from early diagnosis to drug discovery, while addressing bias and health disparities.
Kidney Cancer Awareness Month
By The Cancer News Team
March is Kidney Cancer Awareness Month, highlighting genitourinary cancers, immunotherapy, and global efforts by Binaytara to improve cancer care equity.
Kidney Cancer Awareness Month
By The Cancer News Team
March is Kidney Cancer Awareness Month, highlighting genitourinary cancers, immunotherapy, and global efforts by Binaytara to improve cancer care equity.
Kidney Cancer Awareness Month
By The Cancer News Team
March is Kidney Cancer Awareness Month, highlighting genitourinary cancers, immunotherapy, and global efforts by Binaytara to improve cancer care equity.